• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在实现基因疗法以满足未满足医疗需求方面的全球监管进展。

Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs.

作者信息

Drago Daniela, Foss-Campbell Betsy, Wonnacott Keith, Barrett David, Ndu Adora

机构信息

Biogen, Inc., Global Safety and Regulatory Sciences, Cambridge, MA, USA.

American Society of Gene and Cell Therapy, Policy and Advocacy, Milwaukee, WI, USA.

出版信息

Mol Ther Methods Clin Dev. 2021 Apr 5;21:524-529. doi: 10.1016/j.omtm.2021.04.001. eCollection 2021 Jun 11.

DOI:10.1016/j.omtm.2021.04.001
PMID:33997101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8099595/
Abstract

The rapid expansion of the gene therapy pipeline in recent years offers significant potential to treat diseases with great unmet medical need. However, the unique nature of these therapies poses challenges to regulating them within traditional frameworks, even when developing in a single country. Various factors exacerbate the issues in commercializing products across regions, including the lack of established regulatory frameworks for developing gene therapy products in many jurisdictions. While some countries have established separate regulatory frameworks for advanced therapies/regenerative medicine products, differences exist between them. Recommended solutions to overcome these hurdles include fostering convergence among countries with separate regulatory frameworks for these products and utilizing reliance and recognition for countries without such frameworks. Additionally, regulators who choose to establish new dedicated frameworks for regulating gene therapies should consider the inclusion of key elements such as expedited regulatory pathways that offer early engagement with regulators, innovative clinical trial design, and adequate post-market confirmatory studies. Increasing the alignment of regulatory pathways across countries will be crucial to facilitating the development of, and access to, gene therapies on a global scale.

摘要

近年来基因治疗产品线的迅速扩张为治疗存在巨大未满足医疗需求的疾病提供了巨大潜力。然而,这些疗法的独特性质给在传统框架内对其进行监管带来了挑战,即使是在单个国家开展研发也是如此。各种因素加剧了跨地区产品商业化的问题,包括许多司法管辖区缺乏针对基因治疗产品研发的既定监管框架。虽然一些国家已经为先进疗法/再生医学产品建立了单独的监管框架,但它们之间存在差异。克服这些障碍的建议解决方案包括促进对这些产品有单独监管框架的国家之间的趋同,并对没有此类框架的国家采用依赖和认可的方式。此外,选择为基因治疗建立新的专门监管框架的监管机构应考虑纳入关键要素,如提供与监管机构早期接触的加速监管途径、创新的临床试验设计以及充分的上市后确证性研究。加强各国监管途径的一致性对于在全球范围内促进基因治疗的开发和可及性至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1178/8099595/80b693cfa3f1/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1178/8099595/80b693cfa3f1/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1178/8099595/80b693cfa3f1/fx1.jpg

相似文献

1
Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs.在实现基因疗法以满足未满足医疗需求方面的全球监管进展。
Mol Ther Methods Clin Dev. 2021 Apr 5;21:524-529. doi: 10.1016/j.omtm.2021.04.001. eCollection 2021 Jun 11.
2
Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.基于先进治疗药物的再生牙科治疗的前景:现状、与全球医学趋势的比较及未来展望。
J Endod. 2020 Sep;46(9S):S175-S188. doi: 10.1016/j.joen.2020.06.026.
3
Tuberculosis结核病
4
Proceedings: international regulatory considerations on development pathways for cell therapies.会议记录:细胞疗法开发途径的国际监管考量
Stem Cells Transl Med. 2014 Aug;3(8):879-87. doi: 10.5966/sctm.2014-0122. Epub 2014 Jul 18.
5
Orphan Medicines for Pediatric Use: A Focus on the European Union.儿科孤儿药:以欧盟为例。
Clin Ther. 2019 Dec;41(12):2630-2642. doi: 10.1016/j.clinthera.2019.10.006. Epub 2019 Nov 5.
6
Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future.全球不同领域的先进疗法和监管框架:过去、现在和未来。
Clin Ther. 2021 May;43(5):e103-e138. doi: 10.1016/j.clinthera.2021.02.006. Epub 2021 Apr 21.
7
Innovative regenerative medicines in the EU: a better future in evidence?欧盟的创新再生医学:更美好的未来是否有迹可循?
BMC Med. 2017 Mar 8;15(1):49. doi: 10.1186/s12916-017-0818-4.
8
Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines.化学制造和控制开发、行业对大流行疗法和疫苗制造和供应的反思。
AAPS J. 2022 Sep 27;24(6):101. doi: 10.1208/s12248-022-00751-9.
9
REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.英国和法国基于细胞的再生疗法的报销情况。
Med Law Rev. 2016 Spring;24(2):234-58. doi: 10.1093/medlaw/fww009. Epub 2016 Apr 15.
10
Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations.罕见病的先进再生医学:行业赞助商投资动机的综述。
Ther Innov Regul Sci. 2024 Nov;58(6):1190-1199. doi: 10.1007/s43441-024-00690-x. Epub 2024 Sep 10.

引用本文的文献

1
Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions.前列腺癌中基于血液和尿液的生物标志物:当前进展、临床应用及未来方向
J Liq Biopsy. 2025 Jun 16;9:100305. doi: 10.1016/j.jlb.2025.100305. eCollection 2025 Sep.
2
mTORopathies in Epilepsy and Neurodevelopmental Disorders: The Future of Therapeutics and the Role of Gene Editing.癫痫和神经发育障碍中的mTOR病:治疗的未来与基因编辑的作用
Cells. 2025 Apr 30;14(9):662. doi: 10.3390/cells14090662.
3
Advances and Challenges in Gene Therapy for Inherited Retinal Dystrophies: A Comprehensive Review.

本文引用的文献

1
Clinical Development of Gene Therapies: The First Three Decades and Counting.基因疗法的临床开发:头三十年及未来发展
Mol Ther Methods Clin Dev. 2020 Oct 10;19:387-397. doi: 10.1016/j.omtm.2020.10.004. eCollection 2020 Dec 11.
2
Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals.减轻先进疗法监管评估中的证据缺陷:与其他生物制品的比较研究
Mol Ther Methods Clin Dev. 2020 Jun 3;18:269-279. doi: 10.1016/j.omtm.2020.05.035. eCollection 2020 Sep 11.
3
Regulatory watch: European regulatory experience with advanced therapy medicinal products.
遗传性视网膜营养不良基因治疗的进展与挑战:综述
Cureus. 2024 Sep 22;16(9):e69895. doi: 10.7759/cureus.69895. eCollection 2024 Sep.
4
Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines.细胞和基因治疗在美国和欧盟的临床应用开发:监管指南摘要。
Curr Gene Ther. 2024;25(1):10-21. doi: 10.2174/0115665232306205240419091414.
5
Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape.探索基因疗法的可及性:以保加利亚在欧盟监管环境下的情况为例
Healthcare (Basel). 2024 Feb 11;12(4):458. doi: 10.3390/healthcare12040458.
6
Search, identification, and curation of cell and gene therapy product regulations using augmented intelligent systems.使用增强智能系统搜索、识别和整理细胞与基因治疗产品法规。
Front Med (Lausanne). 2023 Mar 6;10:1072767. doi: 10.3389/fmed.2023.1072767. eCollection 2023.
7
Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives.基因治疗神经肌肉疾病:健康经济挑战与未来展望。
J Neuromuscul Dis. 2022;9(6):675-688. doi: 10.3233/JND-221540.
8
Gene Therapy and Hemophilia: Where Do We Go from Here?基因疗法与血友病:我们将何去何从?
J Blood Med. 2022 Oct 6;13:559-580. doi: 10.2147/JBM.S371438. eCollection 2022.
9
Gene therapy in haemophilia: literature review and regional perspectives for Turkey.血友病的基因治疗:文献综述及土耳其的区域视角
Ther Adv Hematol. 2022 Jul 23;13:20406207221104591. doi: 10.1177/20406207221104591. eCollection 2022.
10
Planning for progress: A US regulatory approach to advancing the clinical development of gene therapies.规划以取得进展:美国推进基因疗法临床开发的监管方法。
Mol Ther. 2022 Jul 6;30(7):2397-2400. doi: 10.1016/j.ymthe.2022.05.005. Epub 2022 May 18.
监管观察:欧洲在先进治疗药品方面的监管经验
Nat Rev Drug Discov. 2019 Jan;18(1):8-9. doi: 10.1038/nrd.2018.200. Epub 2018 Nov 30.
4
Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments.解决基因治疗的价值问题,增加患者获得变革性治疗的机会。
Mol Ther. 2018 Dec 5;26(12):2717-2726. doi: 10.1016/j.ymthe.2018.10.017. Epub 2018 Oct 30.
5
Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence.登记处对加强细胞和基因治疗证据的贡献。
Mol Ther. 2018 May 2;26(5):1172-1176. doi: 10.1016/j.ymthe.2018.04.007. Epub 2018 Apr 21.
6
Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan.美国、欧盟和日本基因治疗产品的监管考量
Yale J Biol Med. 2017 Dec 19;90(4):683-693. eCollection 2017 Dec.
7
Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.基因治疗的监管与科学进展:临床应用及欧洲支持性监管框架的现状
Front Med (Lausanne). 2017 Oct 26;4:182. doi: 10.3389/fmed.2017.00182. eCollection 2017.
8
New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.日本针对基因治疗和细胞治疗产品的临床研究及上市许可的新监管框架。
Curr Gene Ther. 2017;17(1):17-28. doi: 10.2174/1566523217666170406123231.
9
Innovative regenerative medicines in the EU: a better future in evidence?欧盟的创新再生医学:更美好的未来是否有迹可循?
BMC Med. 2017 Mar 8;15(1):49. doi: 10.1186/s12916-017-0818-4.
10
Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.比较日本新的再生医学产品快速审批立法与美国和欧盟现行制度。
J Tissue Eng Regen Med. 2018 Feb;12(2):e1056-e1062. doi: 10.1002/term.2428. Epub 2017 Jun 27.